Citigroup’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-11,270
Closed -$22.6M 6896
2020
Q4
$22.6M Sell
11,270
-1,025
-8% -$1.63M 0.01% 956
2020
Q3
$13.2M Sell
12,295
-1,555
-11% -$1.78M 0.01% 1169
2020
Q2
$16.5M Sell
13,850
-3,365
-20% -$2.92M 0.01% 947
2020
Q1
$7.76M Buy
17,215
+9,330
+118% +$8.49M 0.01% 1330
2019
Q4
$9.07M Sell
7,885
-235
-3% -$211K 0.01% 1572
2019
Q3
$5.02M Buy
8,120
+595
+8% +$494K ﹤0.01% 1938
2019
Q2
$7.55M Buy
7,525
+4,700
+166% +$4.55M 0.01% 1611
2019
Q1
$3.38M Sell
2,825
-400
-12% -$416K ﹤0.01% 2139
2018
Q4
$2.12M Buy
3,225
+2,400
+291% +$2.52M ﹤0.01% 2609
2018
Q3
$1.53M Buy
825
+430
+109% +$845K ﹤0.01% 3009
2018
Q2
$750K Sell
395
-495
-56% -$872K ﹤0.01% 3668
2018
Q1
$1.41M Buy
890
+390
+78% +$726K ﹤0.01% 2923
2017
Q4
$779K Buy
500
+400
+400% +$612K ﹤0.01% 3605
2017
Q3
$171K Buy
+100
New +$139K ﹤0.01% 5115

Other funds holding LABU

Citigroup's LABU Position: Q1 2026 in Review

Citigroup sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2026, closing a stake of 1 share — an estimated $159 sold.

Citigroup first reported a position in LABU in Q2 2015 and held it in 32 quarters. The position peaked at $12.8M in Q3 2017. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • Citigroup reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 Direxion Daily S&P Biotech Bull 3X ETF share in Q1 2026, an estimated $159.
  • Citigroup first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2015 and held it in 32 quarters.
  • Citigroup's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $12.8M in Q3 2017.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.